About Retinoic acid-induced protein 2
Retinoic acid-induced protein 2 (RAI2) is a protein
from Homo sapiens identified by UniProt accession
Q9Y5P3, 530 residues long.
MolForge cross-references it against 0 known binders and
83 disease associations.
Target properties
| Protein name | Retinoic acid-induced protein 2 |
| UniProt accession | Q9Y5P3 |
| Gene | RAI2 |
| Organism | Homo sapiens |
| Length | 530 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (83)
Diseases linked to this target (Open Targets).
- prurigo · score 0.25
- Dextrocardia · score 0.11
- neoplasm · score 0.06
- Gollop-Wolfgang complex · score 0.05
- hepatocellular carcinoma · score 0.05
- gonorrhea · score 0.05
- tibia, hypoplasia or aplasia of, with polydactyly · score 0.05
- Blount disease · score 0.05
- breast cancer · score 0.05
- acheiropody · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y5P3-F1 | alphafold | PREDICTED | 50.02 | — |
Amino-acid sequence (530 residues)
MDDLQSQNLS MDMTDSPPAL ANNRLENGMA QLITTEAWNI NSTDLVKKAL VTVPAPSILN PPAESQSGMA LKVAATVLQP LCLGESPVVM PIHMQVEGSS APELNPNGNA TYVMTTQGPV QLPVVLEQHV FQHLNSPLVL PQEAPCSSST IHNNLFQGAE DPEAQPQLLD LRIPSQPQEP TLPFEAVLQN LFPSQGTLGP PPCQPPPGYA PVPPQPFSSP LSPLVPPATL LVPYPVIVPL PVPVPIPIPI PMPQSSESKF SSSFPKPPSS FGLHPFKGTQ TPLEKDELKP FDILQPKEYF QLSRHTVIKM GSENEALDLS MKSVPWLKAG EVSPPIFQED AALDLSVAAH RKSEPPPETL YDSGASVDSS GHTVMEKLPS GMEISFAPAT SHEAPAMMDS HISSSDAATE MLSQPNHPSG EVKAENNIEM VGESQAAKVI VSVEDAVPTI FCGKIKGLSG VSTKNFSFKR EDSVLQGYDI NSQGEESMGN AEPLRKPIKN RSIKLKKVNS QEIHMLPIKK QRLATFFPRK
Explore Retinoic acid-induced protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets